Provision of Multidrug-resistant tuberculosis (MDR-TB) and Extensively drug-resistant tuberculosis (XDR-TB) treatment

NHS England are inviting Expressions of Interests from suitably experienced, competent and skilled providers wishing to demonstrate compliance with the requirements as set out in this notice for the provision of Bedaquiline and Delamanid for defined patients with Multidrug-Resistant / Extensively Drug-resistant Tuberculosis . NHS England is seeking Expressions of Interests from providers that can provide Bedaquiline and Delamanid that meet the specific terms set out in the NHS England Policy and Service Specification.

Interested providers must ensure they meet the relevant criteria in order to express their interest. In making an EoI, potential providers of this service must have the ability to: -Meet the contract terms set out in the NHS Standard contract: http://www.england.nhs.uk/nhs-standard-contract/15-16/ -Provide regional tertiary referral units with dedicated negative pressure rooms and outpatients facilities; -Annual case load of at least 50 TB index cases; -Provide onsite or formal links with, and rapid access to, specialist paediatric and HIV services; -Provide formal links to a thoracic surgical unit; -Provide access to rapid molecular diagnostics; -Offer IV antibiotics to outpatients; -Provide dedicated outreach and DOT service; -Provide a multi-disciplinary team (MDT) with representation from the -Centre’s microbiology and pharmacy teams. If your organisation expect to meet these requirements then you must register your interest by accessing the Arden & GEM Bravo Solutions e-procurement portal and by downloading the “NHS England – MDRXDRTB” Expression of Interest Proforma’ at the following address: https://ardengemcsu.bravosolution.co.uk